Shares of Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) traded up 11.8% on Thursday . The company traded as high as $7.95 and last traded at $7.95, with a volume of 117,867 shares traded. The stock had previously closed at $7.11.

A number of analysts recently weighed in on the stock. Leerink Swann restated a “buy” rating on shares of Adaptimmune Therapeutics PLC – in a research note on Friday, April 8th. Zacks Investment Research raised Adaptimmune Therapeutics PLC – from a “hold” rating to a “buy” rating and set a $9.75 price target for the company in a report on Tuesday, July 12th. Six analysts have rated the stock with a buy rating, Adaptimmune Therapeutics PLC – presently has a consensus rating of “Buy” and a consensus price target of $15.94.

The stock’s 50-day moving average price is $8.82 and its 200 day moving average price is $8.73. The firm’s market capitalization is $536.55 million.

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) last issued its quarterly earnings results on Thursday, May 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.03. On average, analysts anticipate that Adaptimmune Therapeutics PLC – will post ($1.12) EPS for the current fiscal year.

In other news, Director Orbimed Advisors Llc acquired 1,712,400 shares of Adaptimmune Therapeutics PLC – stock in a transaction dated Tuesday, May 24th. The shares were acquired at an average cost of $10.42 per share, with a total value of $17,843,208.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Charles Elliott Sigal acquired 45,000 shares of Adaptimmune Therapeutics PLC – stock in a transaction dated Wednesday, May 18th. The stock was purchased at an average cost of $1.53 per share, for a total transaction of $68,850.00. Following the completion of the purchase, the director now directly owns 52,938 shares in the company, valued at $80,995.14. The disclosure for this purchase can be found here.

Several institutional investors have recently added to or reduced their stakes in ADAP. Jennison Associates LLC raised its position in Adaptimmune Therapeutics PLC – by 0.3% in the fourth quarter. Jennison Associates LLC now owns 486,948 shares of the company’s stock valued at $5,873,000 after buying an additional 1,547 shares in the last quarter. Tekla Capital Management LLC increased its stake in shares of Adaptimmune Therapeutics PLC – by 5.3% in the fourth quarter. Tekla Capital Management LLC now owns 296,934 shares of the company’s stock valued at $3,581,000 after buying an additional 15,000 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Adaptimmune Therapeutics PLC – during the fourth quarter valued at approximately $1,700,000.

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.